Skip to main content
¿Necesita servicios de traducción?
Comuníquese con nuestra mesa de ayuda 24/7/365 al 877-635-9545.

Update: First Humira® Biosimilar Now Available in U.S.

On January 31st, Amgen introduced Amjevita™ (adalimumab) citrate-free injection, a biosimilar to Humira® (adalimumab) injection 50mg/mL. Amjevita™ is the first of several Humira® biosimilars to become available in the United States. Additional biosimilars, including some that will be classified as interchangeable with Humira®, are expected to launch in the second half of 2023. Amjevita™ is approved for treating most of the same inflammatory conditions as Humira®, with the exception of hidradenitis suppurativa and uveitis. ProAct is currently conducting a value assessment and will be adding it to our formulary within the next 60 days. Amjevita™ is available at our specialty pharmacy, Noble Health Services.

Update: First Humira® Biosimilar Now Available in U.S. hero image
ProAct Logo ProAct Logo ProAct Logo
mobile image tablet image desktop image